Phase I clinical trial: Pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 6, 1998, Pages 312-319

  Roh, J K ^a,d   Rha, S Y ^a   Lee, C I ^a   Lee, K H ^a   Lee, J J ^b   Shim, H J ^b   Lee, S D ^b   Kim, W B ^b   Yang, J ^b   Kim, S H ^c   Lee, M G ^c  

^a Yonsei University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c Seoul National University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

DA 125; Pharmacokinetics; Phase I study; Side effects

Indexed keywords

ANTHRACYCLINE; GALARUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0031841841     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baik NG, Ahn BO, Lee SB, Kim WB, Yang J, Kim MS, Kim JH, Park JW, Jung HH, Roh JK, Watanabe T 1994 Less cardiotoxicity of DA-125, a novel anthracycline derivative, compared to doxorubicin (DXR). Proc Am Assoc Cancer Res 35: 410
2. Chiou WL 1978 Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6: 539-546
3. Chiou WL 1979 New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. J Pharm Sci 68: 1067-1069
4. Choi YJ, Lee HJ, Kwon JW, Kim WB, Lee MG 1996 Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 94: 181-192
5. Choi YJ, Lee HJ, Kwon JW, Kim WB, Yang J, Lee MG 1998 Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. Biopharm Drug Dispos 19: 79-89
6. Gibaldi M, Perrier D 1982 Pharmacokinetics (2nd edn). Marcel Dekker, New York
7. Kim SH, Choi YM, Lee MG 1993 Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21: 1-17
8. Kim YG, Yoon EJ, Yoon WH, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG 1996 Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharm Drug Dispos 17: 183-195
9. Lee SD, Park JB, Lee WI, Shim HJ, Lee ED, Lee JI, Kim WB, Yang J, Kim C-K, Lee MG 1995 Pharmacokinetics and antitumor activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. Biopharm Drug Dispos 16: 489-505
10. Lee SD, Lee WI, Shim HJ, Lee ED, Kim WB, Yang J, Kim C-K, Lee MG 1996 Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. J Clin Pharm Ther 21: 201-213
11. Park JB, Ahn BO, Kim WB, Yang J, Kim SJ, Park JG, Roh JK 1994 Preclinical activityof DA-125, a new anthracycline derivative: Comparative study with doxorubicin (DXR). Proc Am Assoc Cancer Res 35: 410
12. Shim HJ, Lee ED, Yoon EJ, Lee SD, Kim WB, Yang J, Lee MG 1994a Simultaneous determination of a new anthracycline, DA-125, and its metabolites M1, M2, M3, and M4 in plasma and urine by high-performance liquid chromatography. J Chromatogr B 656: 407-414
13. Shim HJ, Lee ED, Yoon EJ, Lee SD, Kim WB, Yang J, Lee MG 1994b Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM or FT-ADM to rats. A new adriamycin analog containing fluorine. Int J Pharm 103: 147-154
14. Yang J, Kim WB, Kim KS, Rhu HM 1993 Chemical, physicochemical, and pharmacological studies on the DA-125, a new anticancer drug. Second Congress of New Drug Development, Seoul National University, Seoul, Korea, April 15, Abstract 36
15. Yoon EJ, Lee ED, Yoon WH, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG 1994a Pharmacokinetics, tissue distribution, and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine. Int J Pharm 109: 181-187
16. Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG 1996 Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogs containing fluorine. Biopharm Drug Dispos 17: 373-420
17. Yoon EJ, Shim HJ, Lee JJ, Lee SD, Kim WB, Yang J, Lee MG 1997 Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Drug Metab Dispos 25: 66-74